| 12/21/2007 | CV | Nuvelo files $60 million debt securities, stock shelf registration
|
| 11/2/2006 | BT | Nuvelo more than doubles cash reserve to $157.2 million
|
| 9/5/2006 | BT | Nuvelo reports Anthem TIMI 32 trial shows higher doses of rNAPc2 reduce ischemia
|
| 9/5/2006 | BT | Nuvelo completes enrollment in alfimeprase phase 3 studies
|
| 7/6/2006 | BT | Nuvelo: Alfimeprase study yields positive results for central venous catheter occlusion
|
| 6/29/2006 | BTCVHY | Nuvelo files automatic shelf
|
| 6/16/2006 | BT | Nuvelo says it will shift emphasis to oncology programs
|
| 6/1/2006 | BT | Nuvelo completes phase 2 trial evaluating rNAPc2 in acute coronary syndromes
|
| 5/5/2006 | BT | Nuvelo says 1Q net loss $19.7 million, to complete phase 3 alfimeprase trials this year
|
| 3/24/2006 | BT | JMP drops Nuvelo
|
| 2/27/2006 | BT | Nuvelo, Bayer begin second phase 3 trial of alfimeprase for catheter occlusion
|
| 2/27/2006 | BT | Nuvelo reports net loss of $71.1 million for 2005
|
| 2/6/2006 | BT | Nuvelo greenshoe exercised, raising follow-on stock issue to $119.6 million
|
| 1/31/2006 | BT | New Issue: Nuvelo raises $104 million in follow-on of 6.5 million shares at $16 vs. $16.03 close
|
| 1/31/2006 | BT | Market Commentary: Nuvelo zooms after deal; SGX cuts guidance, prices at low end; Sepracor soars; BioMarin bounces
|
| 1/24/2006 | BT | Nuvelo plans follow-on of 5.5 million shares via JP Morgan, Deutsche Bank
|
| 1/24/2006 | BT | Market Commentary: Nuvelo, Tercica toss hats in ring; Serono plunges on lack of suitors; Imclone results miss, seeks merger
|
| 1/23/2006 | BT | Nuvelo receives FDA fast track status for alfimeprase
|
| 1/23/2006 | BT | JMP cuts Nuvelo to market perform
|
| 1/6/2006 | BT | Nuvelo reiterated by JMP at market outperform
|
| 1/5/2006 | BT | Nuvelo to partner with Bayer on alfimeprase in deal worth up to $385 million
|
| 1/5/2006 | BT | Market Commentary: Advancis sale of Keflex stumbles; Nuvelo spikes on Bayer pact; buyers snap up Nektar, MannKind
|
| 12/14/2005 | BT | Nuvelo gets FDA agreement on SPA for phase 3 alfimeprase trial in acute peripheral arterial occlusion
|
| 11/14/2005 | BT | Nuvelo says trial shows rNAPc2 is well-tolerated, has acceptable safety profile for acute coronary syndromes
|
| 11/8/2005 | BT | Nuvelo gets additional orphan drug designation for alfimeprase
|
| 11/2/2005 | BT | JMP reiterates Nuvelo at outperform
|
| 10/28/2005 | BT | Montgomery & Co. initiates Nuvelo coverage
|
| 8/5/2005 | BT | Nuvelo kept by JMP at market outperform
|
| 8/5/2005 | PP | Market Commentary: PIPE volume eases as week ends, stocks dip; Benihana closes $20 million private placement
|
| 8/4/2005 | PP | Market Commentary: PIPE volume trails off again on lower stocks; Nuvelo raises $75 million from equity line
|
| 8/4/2005 | BTPP | New Issue: Nuvelo receives equity line for up to $75 million
|
| 7/18/2005 | BT | Nuvelo initiated by Global Crown at overweight
|
| 7/14/2005 | BTCVHY | Nuvelo files $100 million debt, preferred, stock shelf
|
